KACTUS Publishes Framework for 2+1 and Trispecific TCE Scaffold Design

WALTHAM, MA - April 23, 2026 - - KACTUS has published a technical framework for engineering 2+1 and trispecific T-cell engager therapeutics, addressing structural scaffold challenges for drug ...
Capitalbolsa

Fapon Biopharma to Present Next-Generation CD3/TCR VHH TCE Platform at 19th Annual European Life Sciences CEO Forum

ZURICH, March 4, 2026 /PRNewswire/ -- Fapon Biopharma today announced that Dr. Kaiqing Zhang, Ph.D., Associate Director of Business/Corporate Development, will deliver a company presentation at the ...
BioWorld

First-in-class trispecific antibody PIT-565 demonstrates robust efficacy in preclinical studies

Treatment with anti-CD19 bispecific T-cell engager and CAR T therapies can lead to T-cell exhaustion and treatment failure. Novartis AG’s first-in-class anti-CD19, anti-CD3 and anti-CD2 IgG-like ...
The Scientist

Infographic: Understanding CAR-T vs TCR Approaches

(1) A chimeric antigen receptor (CAR) is a modular, synthetic receptor that endows T cells with different targeting abilities. Several emerging engineering approaches aim to improve the safety, ...